Day: December 3, 2019
TUCSON, Ariz., Dec. 03, 2019 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Friday, December 13th in Boston, Massachusetts.The event will feature a presentation by Laura E. Benjamin, Ph.D., Founder and CEO, Oncologie, LTD, who will discuss the future of precision medicine and its potential to bring innovative new medicines to cancer patients globally. Oncologie and HTG are partnering on the development of biomarkers associated with Oncologie’s immuno-oncology pipeline. Laura E. Benjamin will be available at the conclusion of the event to answer any questions.HTG’s management team will also discuss the company’s Pharma partnership model and its...
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Written by Customer Service on . Posted in Public Companies.
First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 expression was demonstrated on cancer-associated cells after eight weeks of treatment with leronlimabA second patient with metastatic breast cancer has been enrolled under an emergency use investigational new drugVANCOUVER, Washington, Dec. 03, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional early Phase 1b/2 clinical trial results evaluating leronlimab (PRO 140) patients with CCR5+ metastatic triple-negative breast...
Ferrellgas Collecting Winter Clothing Items for Those in Need
Written by Customer Service on . Posted in Public Companies.
OVERLAND PARK, Kan., Dec. 03, 2019 (GLOBE NEWSWIRE) — As a company that serves the propane needs of homes, businesses, and farms across the country, Ferrellgas knows a thing or two about keeping America warm. This year Ferrellgas is once again asking its customers—and all the members of the thousands of communities it serves—to help spread even more warmth throughout the area this holiday season.Giving Tuesday, celebrated each year on the Tuesday immediately following Thanksgiving, encourages individuals, groups, and organizations to make a tangible and positive impact within their respective communities. With the backdrop of this global generosity initiative, hundreds of Ferrellgas offices across the country are collecting new and gently used coats, hats, scarves, and gloves as part of its Share The Warmth campaign. This program,...
Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
Written by Customer Service on . Posted in Public Companies.
First IND clearance of a clinical candidate derived from Atreca’s differentiated drug discovery platform Phase 1b clinical trial in patients with solid tumors to begin in early 2020REDWOOD CITY, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application. Atreca expects to initiate a first-in-human Phase 1b clinical trial of ATRC-101 in patients with solid tumors in early 2020.“The FDA’s clearance of our IND application for ATRC-101 is a significant milestone for Atreca and validates the ability...
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
Written by Customer Service on . Posted in Public Companies.
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) — Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib. Cerdulatinib is a dual inhibitor of the Janus kinase (JAK) and spleen tyrosine kinase (Syk) pathways, which Dermavant is evaluating as a differentiated topical treatment option for vitiligo and other inflammatory skin conditions such as atopic dermatitis.“With vitiligo affecting an estimated 65-95 million people worldwide, including approximately 2.4 million people in the U.S., I am excited to announce that the first vitiligo patient...
Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan
Written by Customer Service on . Posted in Public Companies.
MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) — Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.“We appreciate FDA’s guidance during the resubmission period and look forward to working closely with the Agency during the BLA review,” said Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics. “We are pleased to have reached this important milestone and believe that sacituzumab govitecan,...
Adam Fishman, Esq. to Join Barrel Energy Advisory Board
Written by Customer Service on . Posted in Public Companies.
LAS VEGAS, Dec. 03, 2019 (GLOBE NEWSWIRE) — Barrel Energy Inc., (OTC Markets: BRLL) (the “Company” or “Barrel”) is pleased to announce that Adam Fishman, Esq. will join the company as Managing Director Israel and will focus on business opportunities in Israel, primarily for Military and Law Enforcement uses. Fishman holds dual U.S./Israeli citizenship. He was in-house counsel for United Airlines before immigrating to Israel in 2005, where he became V.P. of Legal Affairs and Director of Development for a corporate financial and technology consultancy. Mr. Fishman has developed significant relationships in Israeli hi-tech and innovation, security and governmental sectors. He has also served in professional leadership capacities with AIPAC and American Friends of Likud.Barrel’s Chairman, Harpreet Sangha, stated, “We are delighted to...
SilverCrest Announces C$80 Million Bought Deal Financing
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, B.C., Dec. 03, 2019 (GLOBE NEWSWIRE) — SilverCrest Metals Inc. (“SilverCrest” or the “Company”) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the “Underwriters”) led by National Bank Financial Inc., Desjardins Capital Markets and Scotiabank, pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 11,000,000 common shares of the Company (“Shares”) at a price of C$7.28 per Share for aggregate gross proceeds to the Company of C$80,080,000 million (the “Offering”).The Underwriters have been granted an option (the “Over-Allotment Option”), exercisable in whole or in part, at any time within 30 days following the closing of the Offering, to purchase from the Company up to an additional 15% of the Shares offered under the Offering.The Company will pay...
Dimensional Fund Advisors Ltd. : Form 8.3 – Endeavour Mining Corporation – Ordinary shares
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)*Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 17,202 shares.All interests and all short positions should be disclosed.Details of any open stock-settled derivative...
Dimensional Fund Advisors Ltd. : Form 8.3 – Centamin plc – Ordinary shares
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)*Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 3,242,230 shares.All interests and all short positions should be disclosed.Details of any open stock-settled...